Literature DB >> 27245079

Current and Evolving Methods to Visualize Biological Data in Cancer Research.

Puey Ling Chia1, Craig Gedye2, Paul C Boutros2, Paul Wheatley-Price2, Thomas John2.   

Abstract

Although the measurements of clinical outcomes for cancer treatments have become diverse and complex, there remains a need for clear, easily interpreted representations of patients' experiences. With oncology trials increasingly reporting non-time-to-event outcomes, data visualization has evolved to incorporate parameters such as responses to therapy, duration and degree of response, and novel representations of underlying tumor biology. We review both commonly used and newly developed methods to display outcomes in oncology, with a focus on those that have evolved to represent complex datasets.
© The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Year:  2016        PMID: 27245079      PMCID: PMC5017943          DOI: 10.1093/jnci/djw031

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  34 in total

1.  Misleading funnel plot for detection of bias in meta-analysis.

Authors:  J L Tang; J L Liu
Journal:  J Clin Epidemiol       Date:  2000-05       Impact factor: 6.437

Review 2.  The case of the misleading funnel plot.

Authors:  Joseph Lau; John P A Ioannidis; Norma Terrin; Christopher H Schmid; Ingram Olkin
Journal:  BMJ       Date:  2006-09-16

3.  Using Effect Size-or Why the P Value Is Not Enough.

Authors:  Gail M Sullivan; Richard Feinn
Journal:  J Grad Med Educ       Date:  2012-09

4.  Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study.

Authors:  Emilie Lalonde; Adrian S Ishkanian; Jenna Sykes; Michael Fraser; Helen Ross-Adams; Nicholas Erho; Mark J Dunning; Silvia Halim; Alastair D Lamb; Nathalie C Moon; Gaetano Zafarana; Anne Y Warren; Xianyue Meng; John Thoms; Michal R Grzadkowski; Alejandro Berlin; Cherry L Have; Varune R Ramnarine; Cindy Q Yao; Chad A Malloff; Lucia L Lam; Honglei Xie; Nicholas J Harding; Denise Y F Mak; Kenneth C Chu; Lauren C Chong; Dorota H Sendorek; Christine P'ng; Colin C Collins; Jeremy A Squire; Igor Jurisica; Colin Cooper; Rosalind Eeles; Melania Pintilie; Alan Dal Pra; Elai Davicioni; Wan L Lam; Michael Milosevic; David E Neal; Theodorus van der Kwast; Paul C Boutros; Robert G Bristow
Journal:  Lancet Oncol       Date:  2014-11-13       Impact factor: 41.316

Review 5.  Making the investigational oncology pipeline more efficient and effective: are we headed in the right direction?

Authors:  Patricia M LoRusso; Aparna B Anderson; Scott A Boerner; Steven D Averbuch
Journal:  Clin Cancer Res       Date:  2010-12-15       Impact factor: 12.531

6.  Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials.

Authors:  Jonathan A C Sterne; Alex J Sutton; John P A Ioannidis; Norma Terrin; David R Jones; Joseph Lau; James Carpenter; Gerta Rücker; Roger M Harbord; Christopher H Schmid; Jennifer Tetzlaff; Jonathan J Deeks; Jaime Peters; Petra Macaskill; Guido Schwarzer; Sue Duval; Douglas G Altman; David Moher; Julian P T Higgins
Journal:  BMJ       Date:  2011-07-22

7.  Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria.

Authors:  Jedd D Wolchok; Axel Hoos; Steven O'Day; Jeffrey S Weber; Omid Hamid; Celeste Lebbé; Michele Maio; Michael Binder; Oliver Bohnsack; Geoffrey Nichol; Rachel Humphrey; F Stephen Hodi
Journal:  Clin Cancer Res       Date:  2009-11-24       Impact factor: 12.531

8.  Correlation between overall survival and other endpoints in clinical trials of second-line chemotherapy for patients with advanced gastric cancer.

Authors:  Kohei Shitara; Keitaro Matsuo; Kei Muro; Toshihiko Doi; Atsushi Ohtsu
Journal:  Gastric Cancer       Date:  2013-06-05       Impact factor: 7.370

9.  A meta-analysis of probiotic efficacy for gastrointestinal diseases.

Authors:  Marina L Ritchie; Tamara N Romanuk
Journal:  PLoS One       Date:  2012-04-18       Impact factor: 3.240

10.  Statistical issues and challenges in immuno-oncology.

Authors:  Tai-Tsang Chen
Journal:  J Immunother Cancer       Date:  2013-10-21       Impact factor: 13.751

View more
  5 in total

Review 1.  Independent Drug Action in Combination Therapy: Implications for Precision Oncology.

Authors:  Deborah Plana; Adam C Palmer; Peter K Sorger
Journal:  Cancer Discov       Date:  2022-03-01       Impact factor: 38.272

2.  A Single Visualization Technique for Displaying Multiple Metabolite-Phenotype Associations.

Authors:  Mir Henglin; Teemu Niiranen; Jeramie D Watrous; Kim A Lagerborg; Joseph Antonelli; Brian L Claggett; Emmanuella J Demosthenes; Beatrice von Jeinsen; Olga Demler; Ramachandran S Vasan; Martin G Larson; Mohit Jain; Susan Cheng
Journal:  Metabolites       Date:  2019-07-02

3.  Characterizing tumor shrinkage as a measure of clinical benefit for immune checkpoint inhibitors.

Authors:  Thomas Kelleher; Junliang Cai; Nicholas Aj Botwood; Dominic F Labriola
Journal:  J Immunother Cancer       Date:  2021-02       Impact factor: 13.751

4.  Correlation of treatment outcome in sanger/RT‑qPCR KIT/PDGFRA wild‑type metastatic gastrointestinal stromal tumors with next‑generation sequencing results: A single‑center report.

Authors:  Mojca Unk; Alenka Bombač; Barbara Jezeršek Novaković; Vida Stegel; Vita Šetrajčič Dragoš; Olga Blatnik; Gašper Klančar; Srdjan Novaković
Journal:  Oncol Rep       Date:  2022-07-29       Impact factor: 4.136

Review 5.  A Causal Framework for Making Individualized Treatment Decisions in Oncology.

Authors:  Pavlos Msaouel; Juhee Lee; Jose A Karam; Peter F Thall
Journal:  Cancers (Basel)       Date:  2022-08-14       Impact factor: 6.575

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.